1rue: Difference between revisions

From Proteopedia
Jump to navigationJump to search
← Older editNewer edit →
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
OCA (talk | contribs)
Bots, Bureaucrats, journal, Administrators
3,331,613 edits
No edit summary
Line 1: Line 1:
[[Image:1rue.jpg|left|200px]]
{{Seed}}
[[Image:1rue.png|left|200px]]


<!--
<!--
Line 9: Line 10:
{{STRUCTURE_1rue|  PDB=1rue  |  SCENE=  }}  
{{STRUCTURE_1rue|  PDB=1rue  |  SCENE=  }}  


'''RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035'''
===RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035===




==Overview==
<!--
Structures have been determined of three human rhinovirus 14 (HRV14) compensation mutants that have resistance to the antiviral capsid binding compounds WIN 52035 and WIN 52084. In addition, the structure of HRV14 is reported, with a site-directed mutation at residue 1219 in VP1. A spontaneous mutation occurs at the same site in one of the compensation mutants. Some of the mutations are on the viral surface in the canyon and some lie within the hydrophobic binding pocket in VP1 below the ICAM footprint. Those mutant virus strains with mutations on the surface bind better to cells than does wild-type virus. The antiviral compounds bind to the mutant viruses in a manner similar to their binding to wild-type virus. The receptor and WIN compound binding sites overlap, causing competition between receptor attachment and antiviral compound binding. The compensation mutants probably function by shifting the equilibrium in favor of receptor binding. The mutations in the canyon increase the affinity of the virus for the receptor, while the mutations in the pocket probably decrease the affinity of the WIN compounds for the virus by reducing favorable hydrophobic contacts and constricting the pore through which the antiviral compounds are thought to enter the pocket. This is in contrast to the resistant exclusion mutants that block compounds from binding by increasing the bulk of residues within the hydrophobic pocket in VP1.
The line below this paragraph, {{ABSTRACT_PUBMED_7473717}}, adds the Publication Abstract to the page
(as it appears on PubMed at http://www.pubmed.gov), where 7473717 is the PubMed ID number.
-->
{{ABSTRACT_PUBMED_7473717}}


==About this Structure==
==About this Structure==
Line 34: Line 38:
[[Category: Icosahedral virus]]
[[Category: Icosahedral virus]]
[[Category: Rhinovirus coat protein]]
[[Category: Rhinovirus coat protein]]
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Sat May  3 07:55:20 2008''
 
''Page seeded by [http://oca.weizmann.ac.il/oca OCA ] on Mon Jul 28 06:31:10 2008''

Revision as of 03:31, 28 July 2008

File:1rue.png

Template:STRUCTURE 1rue

RHINOVIRUS 14 SITE DIRECTED MUTANT N1219A COMPLEXED WITH ANTIVIRAL COMPOUND WIN 52035

Template:ABSTRACT PUBMED 7473717

About this Structure

1RUE is a Protein complex structure of sequences from Human rhinovirus 14. Full crystallographic information is available from OCA.

Reference

Structural studies on human rhinovirus 14 drug-resistant compensation mutants., Hadfield AT, Oliveira MA, Kim KH, Minor I, Kremer MJ, Heinz BA, Shepard D, Pevear DC, Rueckert RR, Rossmann MG, J Mol Biol. 1995 Oct 13;253(1):61-73. PMID:7473717

Page seeded by OCA on Mon Jul 28 06:31:10 2008

Proteopedia Page Contributors and Editors (what is this?)

OCA

Retrieved from "https://proteopedia.org/index.php?title=1rue&oldid=685602"